Redeye is positive on the new CPT III codes for Paxman’s CIPN device. The codes, effective January 2027, are a key factor for the device’s establishment in the US market. We also look forward to the announcement of preliminary reimbursement rates, expected in summer 2026, which will provide further clarity on commercial potential.
LÄS MER
